Plain-English translation of NCT05508009 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new approach for patients who need a kidney transplant due to serious kidney diseases like lupus nephritis, genetic kidney disorders, or previous transplant rejection. The study combines two procedures: first, you receive a stem cell transplant from a living donor (after special filtering to remove certain immune cells), and then at least three months later, you receive a kidney from that same donor. The goal is to see if this combination allows your body to accept the new kidney without needing lifelong anti-rejection medications.
Most kidney transplant patients must take strong anti-rejection drugs for life, which can cause serious side effects and eventually lead to organ failure. This trial is exploring whether the stem cell transplant can train your immune system to accept the kidney naturally, eliminating the need for these medications and their risks.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will first receive conditioning chemotherapy (the type depends on your specific kidney disease), followed by an infusion of filtered stem cells from your donor. You will then be monitored closely for at least three months to ensure the stem cells engraft and your body is tolerating the transplant. Once engraftment is confirmed, you will receive a kidney transplant from the same donor. After the kidney transplant, your doctors will gradually reduce and eventually stop your anti-rejection medications while closely watching for any signs of rejection. The study will follow you over time to see how well this approach works.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States